Navigation Links
Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
Date:3/28/2013

SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology (still ongoing in the rodent), clinical signs and clinical chemistries. Omeros expects to submit a European Clinical Trial Application (CTA) in the second quarter of this year to initiate clinical trials evaluating OMS721.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, or the acquired immune response to infection. The Company has conducted a series of in vivo studies that suggest that MASP-2 inhibition may have a preventive or therapeutic effect in the treatment of atypical hemolytic uremic syndrome (aHUS), HUS, wet age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), transplant-related complications, ischemia-reperfusion injury, and other immune-related disorders.

The studies reported today in both primates and rodents provide the primary safety data expected to support the initiation of OMS721 clinical studies in mid-year 2013. The pharmacokinetic results in primates demonstrated that subcutaneous administration of OMS721 resulted in maximal inhibition of the lectin pathway within six hours of administration and
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... VICL ) today announced the receipt of ... for costs associated with the ongoing Allovectin-7(R),Immunotherapeutic for ... is funding the Phase 3 pivotal trial of ... scheduled series of,cash payments and equity investments totaling ...
... Atrial ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 ... ever U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic ... to proceed with the pivotal phase of the,study is based on ...
Cached Medicine Technology:Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Smile Squared, ... their product offering to include a US-made toothbrush. For ... child without one. , “Smile Squared was created by ... clinic in Guatemala,” said Eric Cope, President of Smile ... sometimes severe dental problems. But many of the same ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: Digoxin may increase ... (AF) by approximately 20%, according to results from the ... Dr Manesh Patel, director of interventional cardiology and catheterisation ... Carolina, US. The findings suggest that caution may be ... further studies are needed to confirm the observations. , ...
(Date:9/2/2014)... The fact that mechanical heart valves increase risks during ... the ROPAC registry presented for the first time today ... Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of ... of pregnant women with a mechanical heart valve died ... Registry Of Pregnancy And Cardiac disease (ROPAC) is an ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and home medical ... of its new office to be located in Greer, ... Suite D, Greer, SC 29651. This new location will ... convenient location in the Greenville area. , “This is ... hospitals and patients we serve, to ensure that we ...
(Date:9/2/2014)... 2014 Attorney Robert M. Higgins ... of the Year" for Medical Malpractice Law - ... Boston, and has been selected for inclusion in The Best ... in each practice area and designated metropolitan area is honored ... voting averages received during the peer-review assessments. , The ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2
... the process of developing a vaccine called Gardasil against ... is being sought by the organization in Europe and ... MSD has to approve of the marketing authorization for ... to have a decided advantage over GlaxoSmithKline’s Cervarix. Both ...
... (PCRM) has developed an in-house animal serum free diabetes test ... by Linco Research. PCRM started to initiate the development of ... that it is not possible to develop the test kit ... kit uses synthetic medium and the cost and accuracy is ...
... treated with 500 mcg of Aranesp (Darbepoetin alfa) for ... in 70% of patients. //The new drug Aranesp is ... trial with 200 low-risk MDS patients who were administered ... is a pre-leukemia stage in which the bone marrow ...
... conducted by George S. Zubenko, MD, PhD, Professor of Psychiatry ... that genes relating to aging with preserved mental capacity have ... kind and was funded by National Institutes of Health (NIH). ... years old or above. There were equal number of men ...
... Botulinum toxin A or Botox as it is popularly tagged ... for erasing wrinkles and making the facial skin appear fresh ... of Cosmetic Dermatology says that there is more to botox ... BTXA as it is called in medical parlance can also ...
... body thinking that it will fetch happiness. A study has ... mental suffering and woes, and they are far from being ... chances of slim people committing suicide appear to be greater ... ,The research was also extended to studying the European population, ...
Cached Medicine News:Health News:Genetics of Ageing with Preserved Mental Capacity. 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: